Best Practices and Research Advances in Thoracic Oncology: A Regional Series Eastern Europe/Baltic Course 2: Immunotherapy in Lung Cancer-Biomarkers for Immunotherapy

Video Transcription

Video Summary

In this seminar, Yannis Mougios discusses the role of biologists in healthcare, focusing on lung cancer treatment applications. The presentation is divided into four sections: pathology, genomics, biopsies, and toxicity management. Key highlights include the use of PD-L1 as a biomarker, though its limitations in conditions like mesothelioma are noted. The seminar explores various programs and guidelines, such as the FDA's work on standardizing antibody use, and the importance of genomic panels for novel therapeutic approaches. It discusses the use of circulating tumor DNA (ctDNA) in predicting treatment efficacy and early detection of disease progression. Mougios emphasizes the integration of personalized care through 'liquid biopsies,' and how modern tools like spatial transcriptomics and microbiome analysis influence treatment strategies. He concludes with the potential of proteomics in further refining therapeutic strategies. The seminar underscores the evolving landscape of predictive and diagnostic modalities in oncology.

Asset Subtitle

Giannis Mountzios

Keywords

lung cancer

biomarkers

genomic panels

liquid biopsies

ctDNA

proteomics